ReviR Therapeutics Receives FDA Rare Pediatric Disease Designation for RTX-117 in Charcot-Marie-Tooth Disease
ReviR Therapeutics has received FDA Rare Pediatric Disease Designation for RTX-117, its lead candidate for Charcot-Marie-Tooth disease.
ReviR Therapeutics
Private